Obseva SA (NASDAQ:OBSV) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokers have set a one year consensus price target of $21.00 for the company and are anticipating that the company will post ($0.54) earnings per share for the current quarter, according to Zacks. Zacks has also given Obseva SA an industry rank of 159 out of 265 based on the ratings given to its competitors.

OBSV has been the subject of a number of analyst reports. Credit Suisse Group AG initiated coverage on shares of Obseva SA in a research report on Tuesday, February 21st. They issued an “outperform” rating and a $27.00 price objective for the company. Leerink Swann initiated coverage on shares of Obseva SA in a research report on Tuesday, February 21st. They issued an “outperform” rating and a $21.00 price objective for the company. Finally, Jefferies Group LLC initiated coverage on shares of Obseva SA in a research report on Tuesday, February 21st. They issued a “buy” rating and a $21.00 price objective for the company.

Shares of Obseva SA (NASDAQ:OBSV) traded up 2.25% during mid-day trading on Friday, hitting $8.64. 3,814 shares of the stock were exchanged. The stock’s market cap is $256.01 million. Obseva SA has a one year low of $6.11 and a one year high of $14.69. The company has a 50-day moving average of $7.54 and a 200 day moving average of $10.21.

Obseva SA (NASDAQ:OBSV) last posted its quarterly earnings data on Thursday, May 18th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.17. On average, equities analysts predict that Obseva SA will post ($2.11) earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. Baker Avenue Asset Management LP bought a new position in shares of Obseva SA during the first quarter valued at approximately $104,000. Paloma Partners Management Co bought a new position in shares of Obseva SA during the first quarter valued at approximately $131,000. Iguana Healthcare Management LLC bought a new position in shares of Obseva SA during the first quarter valued at approximately $260,000. Spark Investment Management LLC bought a new position in shares of Obseva SA during the first quarter valued at approximately $518,000. Finally, Nexthera Capital LP bought a new position in shares of Obseva SA during the first quarter valued at approximately $521,000.

COPYRIGHT VIOLATION WARNING: “Brokerages Expect Obseva SA (OBSV) to Post ($0.54) Earnings Per Share” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/05/26/brokerages-expect-obseva-sa-obsv-to-post-0-54-earnings-per-share.html.

Obseva SA Company Profile

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.

12 Month Chart for NASDAQ:OBSV

Get a free copy of the Zacks research report on Obseva SA (OBSV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Obseva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva SA and related companies with MarketBeat.com's FREE daily email newsletter.